SecurityGS / Goldman Sachs Group, Inc. (The)
InstitutionOdey Asset Management Group Ltd
Shares0
Value $ 0
Related 271790AF4 / East Coast Pwr L L C Sr Secd 7.536% 06/30/17
38141GFG4 / Goldman Sachs 5.95% Notes 1/18/18
38141GFM1 / Goldman Sachs 6.15% Senior Notes 4/1/18
38144LAB6 / Goldman Sachs 6.25% Senior Notes 9/1/17
38141GFD1 / Goldman Sachs 6.75% Notes 10/1/37
38143VAA7 / Goldman Sachs Cap I Guaranteed Cap Sec 34 02/15/34
381427AA1 / Goldman Sachs Capital Ii 5.793% Fixed-to-floating Rate Normal Automatic Pfd Enhanced Capital Securities 6/1/2043
38144QAA7 / Goldman Sachs Capital Iii Flt Rate Normal Auto Pfd Cap Sec 9/1/2043
38141EA58 / Goldman Sachs Gp 5.375% Senior Notes 03/15/20
38141GRC0 / Goldman Sachs Gp Gs 2.375% 1/22/18
38141GRD8 / Goldman Sachs Gp Gs 3.625% 1/22/23
38141GGM0 / Goldman Sachs Gpoup Inc. 6.25% Senior Notes 02/01/41
38141GDK7 / Goldman Sachs Group 4.750% Notes 07/15/13
38143UAB7 / Goldman Sachs Group 5.15% Bonds 1/15/14
38141GEA8 / Goldman Sachs Group 5 1/8% Notes 01/15/2015
38141GDQ4 / Goldman Sachs Group 5.250% Notes 10/15/13
38141GEE0 / Goldman Sachs Group 5.35% Notes 01/15/16
38141GCM4 / Goldman Sachs Group 5.500% Notes 11/15/14
GS.PRJ / Goldman Sachs Group, 5.50% Dep Shares Fixd/Float Non-Cumul Preferred Stock Ser J
38141GEU4 / Goldman Sachs Group 5.625% Notes 01/15/17
38141GER1 / Goldman Sachs Group 5.75% Senior Notes 10/1/16
GS.PRI / Goldman Sachs Group, 5.95% Dep Shares Non-Cumulative Preferred Stock, Series I
38141GES9 / Goldman Sachs Group 5.95% Notes 1/15/27
38143UAW1 / Goldman Sachs Group 5% Notes 10/1/14
38141GCU6 / Goldman Sachs Group 6.125% Notes 02/15/33
GS.PRB / Goldman Sachs Group, 6.20% Dep Shares Non-cumul Preferred, Stock Series B
GS.PRN / Goldman Sachs Group, 6.30% Dep Shares Non-Cumulative Preferred Stock Series N
GS.PRK / Goldman Sachs Group, 6.375% Dep Sh Fixd/Float Non-Cumul Preferred Stock Series K
38143YAC7 / Goldman Sachs Group 6.45% Notes 5/1/36
GSJ / Goldman Sachs Group, 6.50% Bonds due 11/1/2061
GS.PRA / Goldman Sachs Group, Dep Shares Float Rate Non-cumul Preferred Stock, Series A
GS.PRC / Goldman Sachs Group, Dep Shares Float Rate Non-cumul Preferred Stock, Series C
GS.PRD / Goldman Sachs Group, Dep Shares Float Rate Non-Cumul Preferred Stock, Series D
38141EB32 / Goldman Sachs Group Inc. 1.60% 11/23/15
38141GGT5 / Goldman Sachs Group Inc. 3.30% 05/03/15
38143USC6 / Goldman Sachs Group Inc. 3.625% Senior Notes 02/07/16
38141EA74 / Goldman Sachs Group Inc. 3.7% Senior Notes 08/01/15
38141GGQ1 / Goldman Sachs Group Inc 5.25% 07/27/21
38141GGS7 / Goldman Sachs Group Inc. 5.75% 01/24/22
38141EA66 / Goldman Sachs Group Inc. 6.0% Senior Notes 06/15/20
TFG / Goldman Sachs Group, Inc, Fixed Income Trust, Series 2011-1
38143UMT5 / Goldman Sachs Group Inc Fixed Rt Notes Ser D 3.85% 12/15/2016
GLSSP / Goldman Sachs Group, Inc. (The)
38147MAA3 / Goldman Sachs Group, Inc. (The) Bond
38148BAA6 / Goldman Sachs Group, Inc. (The) Bond
38141E2V0 / Goldman Sachs Group, Inc. (The) Bond
38141E2N8 / Goldman Sachs Group, Inc. (The) Bond
38147QLX2 / Goldman Sachs Group, Inc. (The) Bond
38141E5H8 / Goldman Sachs Group, Inc. (The) Bond
38147QMF0 / Goldman Sachs Group, Inc. (The) Bond
38141GMG6 / Goldman Sachs Group, Inc. (The) Bond
38143UTC5 / Goldman Sachs Group, Inc. (The) Bond
38148BAB4 / Goldman Sachs Group, Inc. (The) Bond
38147QFN1 / Goldman Sachs Group, Inc. (The) RGE ACCRL7.25%28
38141GJA3 / Goldman Sachs Group, Inc. (The) SEUS
38141E5Y1 / Goldman Sachs Grp Inc Mtn Be Fr 4% 03/15/16
38141E5M7 / Goldman Sachs Grp Inc Mtn Be Fr 4.1% 02/15/16
38141E5X3 / Goldman Sachs Grp Inc Mtn Be Fr 4.75% 03/15/18
38141E5N5 / Goldman Sachs Grp Inc Mtn Be Fr 5% 02/15/20
38141E6K0 / Goldman Sachs Grp Inc Mtn Be Fr 5.25% 05/15/14
38141E6H7 / Goldman Sachs Grp Inc Mtn Be Fr 5.4% 04/30/14
38141E6T1 / Goldman Sachs Grp Inc Mtn Be Fr 5.4% 06/15/15
38141E6S3 / Goldman Sachs Grp Inc Mtn Be Fr 5.6% 06/15/15
38141E6M6 / Goldman Sachs Grp Inc Mtn Be Fr 5.85% 05/15/15
38141E6P9 / Goldman Sachs Grp Inc Mtn Be Fr 5.85% 05/15/16
38141E6R5 / Goldman Sachs Grp Inc Mtn Be Fr 6% 05/15/16
38141E6V6 / Goldman Sachs Grp Inc Mtn Be Fr 6% 06/15/16
38141E6J3 / Goldman Sachs Grp Inc Mtn Be Fr 6.5% 04/30/17
38141E6L8 / Goldman Sachs Grp Inc Mtn Be Fr 6.5% 05/15/17
38141E6Q7 / Goldman Sachs Grp Inc Mtn Be Fr 6.5% 05/15/19
38141E6U8 / Goldman Sachs Grp Inc Mtn Be Fr 6.5% 06/15/19
38141E6N4 / Goldman Sachs Grp Inc Mtn Be Fr 6.75% 05/15/19
38141EA33 / Goldman Sachs Grp Inc Mtn Be Senior Notes 6% 05/01/14
GSC / GS Connect S&P GSCI Enhanced Community TR Strategy Index ETN due 5/8/2037
JBK / Lehman ABS Corp Bkd Trust Certs 2004-06, Floating Rate Goldman Sachs Cap I
GJS / Synthetic Fixed-Income Sec STRATS 2006-02, Float Rate Goldman Sachs Group
GS.PRICL / The Goldman Sachs Group, Inc.
38141EA25 / The Goldman Sachs Group Inc. 7.50% Notes 02/15/19
62718QAA3 / The Goldman Sachs Group Inc. Murray Street Investment Trust 1 4.647% Sr Guaranteed Tr 03/09/17

Odey Asset Management Group Ltd closes passive position in GS / Goldman Sachs Group, Inc. (The)

February 14, 2018 - Odey Asset Management Group Ltd has filed a 13F-HR form disclosing ownership of 0 shares of Goldman Sachs Group, Inc. (The) (NYSE:GS) with total holdings valued at $0 USD as of December 31, 2017. Odey Asset Management Group Ltd had filed a previous 13F-HR on November 14, 2017 disclosing 133,850 shares of Goldman Sachs Group, Inc. (The) at a value of $31,748,000 USD. This represents a change in shares of -100.00 percent and a change in value of -100.00 percent during the quarter.

Other investors with closed positions include Paragon Associates & Paragon Associates Ii Joint Venture, Caxton Associates Lp, Arrowgrass Capital Partners (us) Lp, Grantham, Mayo, Van Otterloo & Co. LLC, and Jupiter Asset Management Ltd.

Goldman Sachs Group, Inc. (The) has declared a standard industrial code (sic) of 6211 which is the "Security Brokers, Dealers, and Flotation Companies" industry. Odey Asset Management Group Ltd's top industries are "Mining And Quarrying Of Nonmetallic Minerals, Except Fuels" (sic 14), "Furniture And Fixtures" (sic 25), and "Primary Metal Industries" (sic 33).

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2017-12-31 13F-HR GOLDMAN SACHS GROUP COM 38141G104 0 -100.00 0 -100.00
2017-09-30 13F-HR GOLDMAN SACHS GROUP COM 38141G104 229.55 133,850 -7.15 31,748 -0.75 -2,364 2,125 6.64
2017-06-30 13F-HR GOLDMAN SACHS GROUP COM 38141G104 225.81 144,150 -35.15 31,987 -37.36 -17,645 -1,432 -2.81
2017-03-31 13F-HR GOLDMAN SACHS GROUP COM 38141G104 234.58 222,289 -56.94 51,064 -58.69 -68,967 -3,593 -2.91
2016-12-31 13F-HR GOLDMAN SACHS GROUP COM 38141G104 200.36 516,285 14.00 123,624 69.27 12,707 37,883 51.87
2016-09-30 13F-HR GOLDMAN SACHS GROUP COM 38141G104 154.93 452,866 2.36 73,034 11.10 1,617 5,681 8.64
2016-06-30 13F-HR GOLDMAN SACHS GROUP COM 38141G104 152.78 442,427 -7.47 65,736 -12.42 -5,454 -3,866 -5.15
2016-03-31 13F-HR GOLDMAN SACHS GROUP COM 38141G104 168.60 478,124 4.40 75,056 -9.06 3,400 -10,882 -13.18
2015-12-31 13F-HR GOLDMAN SACHS GROUP COM 38141G104 176.99 457,961 1.96 82,538 5.75 1,555 2,935 3.76
2015-09-30 13F-HR GOLDMAN SACHS GROUP COM 38141G104 191.27 449,174 -52.54 78,048 -60.51 -95,129 -24,446 -12.37
2015-06-30 13F-HR GOLDMAN SACHS GROUP COM 38141G104 198.38 946,517 10.90 197,623 23.18 18,451 18,738 11.68
2015-03-31 13F-HR GOLDMAN SACHS GROUP COM 38141G104 190.90 853,507 -1.14 160,434 -4.13 -1,875 -5,030 -3.01
2014-12-31 13F-HR GOLDMAN SACHS GROUP COM 38141G104 188.70 863,328 194.87 167,339 211.35 107,663 5,930 11.03
2014-09-30 13F-HR GOLDMAN SACHS GROUP COM 38141G104 175.51 292,780 10.48 53,746 21.13 4,876 4,498 10.14
2014-06-30 13F-HR GOLDMAN SACHS GROUP COM 38141G104 165.65 265,000 11.34 44,372 13.79 4,472 904 2.32
2014-03-31 13F-HR GOLDMAN SACHS GROUP COM 38141G104 238,000 38,996

Related SEC Filings

GS / Goldman Sachs Group, Inc. (The) / GOLDMAN SACHS GROUP INC - AMENDMENT NO. 96 TO SCHEDULE 13D (Activist Investment)

2018-03-05 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 File No. 005-56295 ----------------- SCHEDULE 13D/A (Rule 13d-101) Amendment No. 96 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) The Goldman Sachs Group, Inc. (Name of Issuer) Common Stock, par value $.01 per share (Title of Class o (8-0)

GS / Goldman Sachs Group, Inc. (The) / STATE STREET CORP - THE GOLDMAN SACHS GROUP, INC. (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING THE GOLDMAN SACHS GROUP, INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 38141G104 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER

GS / Goldman Sachs Group, Inc. (The) / STATE STREET CORP - THE GOLDMAN SACHS GROUP, INC. (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING THE GOLDMAN SACHS GROUP, INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 38141G104 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER

GS / Goldman Sachs Group, Inc. (The) / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
goldmansachsgroupincthe.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 2 )*       Name of issuer:  Goldman Sachs Group Inc/The     Title of Class of Securities:  Common Stock     CUSIP Number:  38141G104     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is

GS / Goldman Sachs Group, Inc. (The) / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
goldmansachsgroupincthe.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 2 )*       Name of issuer:  Goldman Sachs Group Inc/The     Title of Class of Securities:  Common Stock     CUSIP Number:  38141G104     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...



CUSIP: 38141G104